Coya Therapeutics, Inc. (NASDAQ:COYA) Stock Has Consensus Price Target of $15.33 According to Analysts

Coya Therapeutics, Inc. (NASDAQ:COYA) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $15.33.

A number of equities research analysts have weighed in on the company. Roth Capital restated a “buy” rating and set a $12.00 price target on shares of Coya Therapeutics in a research report on Monday, August 24th. Chardan Capital reissued a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Wednesday, August 12th. HC Wainwright reissued a “buy” rating on shares of Coya Therapeutics in a report on Friday, September 25th. BTIG Research restated a “buy” rating and issued a $16.00 target price on shares of Coya Therapeutics in a research report on Tuesday, September 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Friday, July 17th.

Coya Therapeutics Stock Performance

Shares of COYA opened at $4.18 on Friday. Coya Therapeutics has a 52-week low of $3.71 and a 52-week high of $7.55. The stock’s 50-day simple moving average is $4.78 and its 200 day simple moving average is $4.70. The stock has a market capitalization of $98.06 million, a price-to-earnings ratio of -3.91 and a beta of 0.58.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.07. Coya Therapeutics had a negative return on equity of 52.05% and a negative net margin of 270.22%. The firm had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.13 million. On average, research analysts forecast that Coya Therapeutics will post -1.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Coya Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Allworth Financial LP increased its position in shares of Coya Therapeutics by 1,200.0% in the second quarter. Allworth Financial LP now owns 13,000 shares of the company’s stock valued at $76,000 after acquiring an additional 12,000 shares during the period. AXQ Capital LP bought a new position in Coya Therapeutics during the 2nd quarter valued at approximately $116,000. Long Corridor Asset Management Ltd bought a new position in Coya Therapeutics during the 2nd quarter valued at approximately $227,000. ADAR1 Capital Management LLC purchased a new stake in Coya Therapeutics in the 1st quarter worth approximately $161,000. Finally, Renaissance Technologies LLC lifted its holdings in Coya Therapeutics by 55.4% in the 1st quarter. Renaissance Technologies LLC now owns 103,964 shares of the company’s stock worth $410,000 after buying an additional 37,064 shares during the period. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies that regulate neuroinflammation and support immune-system function. The company’s research centers on regulatory T cells, or Tregs, immune cells that help control excessive inflammatory responses. Coya is developing treatments intended for neurodegenerative diseases in which inflammation may contribute to disease progression.

The company’s lead programs include COYA 101, an autologous Treg cell therapy in which a patient’s cells are collected, expanded and activated outside the body, and then administered as a potential treatment for amyotrophic lateral sclerosis (ALS).